{"product_id":"antiplatelet-therapy-in-cardiovascular-disease-hardback-9781118275757","title":"Antiplatelet Therapy in Cardiovascular Disease (Hardback) 9781118275757","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eAntiplatelet Therapy in Cardiovascular Disease\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eRon Waksman (Edited by), R Waksman (Author), Paul A. Gurbel (Edited by), Michael A. Gaglia, Jr. (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781118275757, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 16 May 2014\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e348 pages\u003cbr\u003e23.8 x 15.9 x 2.3 cm, 0.708 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003e“\u003c\/b\u003eWritten by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.”  (\u003ci\u003eKingbook73's Medical Ebook and Video Collection\u003c\/i\u003e, 20 August 2014)\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eEdited by a team of the world’s leading interventional cardiologists and educators, this new book is created with an eye to giving the reader a solid, practical, and clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents.\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003eThis important new book:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eBegins with a concise but thorough discussion of platelet biology and pathophysiology so that readers understand how antiplatelet agents work and why they produce such a varied range of complications, from minor GI upset to potentially life-threatening conditions such as neutropenia, a critical shortage of white blood cells.\u003c\/li\u003e \u003cli\u003eThoroughly covers platelet function testing, including novel techniques.\u003c\/li\u003e \u003cli\u003eClarifies current best practice regarding the use of antiplatelet agents in both chronic and acute cardiovascular disease.\u003c\/li\u003e \u003cli\u003eReviews all types of antiplatelet agents – from aspirin to recently approved drugs – including indications, clinical outcomes, and side effects.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003eWritten by an international “who’s who” of experts in the field, \u003cb\u003e\u003ci\u003eAntiplatelet Therapy in Cardiovascular Disease\u003c\/i\u003e\u003c\/b\u003e also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to interventional cardiologists.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eList of Contributors, viii\u003c\/p\u003e \u003cp\u003eForeword, xix\u003c\/p\u003e \u003cp\u003ePreface, xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Platelet biology and pathophysiology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Platelet Pathophysiology and its Role in Thrombosis, 3\u003cbr\u003e \u003ci\u003ePaul A. Gurbel and Udaya S. Tantry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Platelet Receptors and Drug Targets: COX-1, 8\u003cbr\u003e \u003ci\u003eThomas Hohlfeld and Karsten Schror\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Platelet Receptors and Drug Targets: P2Y12, 14\u003cbr\u003e \u003ci\u003eMarco Cattaneo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Platelet Receptors and Drug Targets: GP IIb\/IIIa, 21\u003cbr\u003e \u003ci\u003eEliano Pio Navarese and Jacek Kubica\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29\u003cbr\u003e \u003ci\u003ePing Zhang, Lidija Covic, and Athan Kuliopulos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Role of Inflammation and Hypercoagulability in Thrombosis, 45\u003cbr\u003e \u003ci\u003ePaul A. Gurbel, Nachiket Apte, and Udaya S. Tantry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Platelet function tests\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7 Light Transmission Aggregometry, 53\u003cbr\u003e \u003ci\u003ePaul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58\u003cbr\u003e \u003ci\u003eMarc Laine, Franck Paganelli, and Laurent Bonello\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 VerifyNow P2Y12 and Plateletworks Assays, 65\u003cbr\u003e \u003ci\u003eMatthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Multiplate Analyzer, 82\u003cbr\u003e \u003ci\u003eMartin Orban and Dirk Sibbing\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Shear Stress-Based Platelet Function Tests, 92\u003cbr\u003e \u003ci\u003eNicoline J. Breet and Jurriën M. ten Berg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Thrombelastography and Other Novel Techniques, 102\u003cbr\u003e \u003ci\u003eUdaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Antiplatelet pharmacology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13 Aspirin, 111\u003cbr\u003e \u003ci\u003eKarsten Schrör and Thomas Hohlfeld\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Cilostazol, 117\u003cbr\u003e \u003ci\u003eSeung-Whan Lee, Duk-Woo Park, and Seung-Jung Park\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Abciximab, 125\u003cbr\u003e \u003ci\u003eJ. Emilio Exaire and Jorge F. Saucedo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Tirofiban, 131\u003cbr\u003e \u003ci\u003eMarco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Eptifibatide, 142\u003cbr\u003e \u003ci\u003eNevin C. Baker and Ron Waksman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Ticlopidine, 150\u003cbr\u003e \u003ci\u003eFabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Clopidogrel, 160\u003cbr\u003e \u003ci\u003eAndrzej Budaj\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Prasugrel, 166\u003cbr\u003e \u003ci\u003eChristoph Varenhorst, Anna Oskarsson, and Stefan James\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Elinogrel, 173\u003cbr\u003e \u003ci\u003eMatthew J. Chung and Sunil V. Rao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Cangrelor, 180\u003cbr\u003e \u003ci\u003eFrancesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Ticagrelor, 193\u003cbr\u003e \u003ci\u003eAnna Oskarsson, Christoph Varenhorst, and Stefan James\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Thrombin Receptor Antagonists, 198\u003cbr\u003e \u003ci\u003eFlavio de Souza Brito and Pierluigi Tricoci\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV: Percutaneous Coronary Intervention and Antiplatelet Therapy\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209\u003cbr\u003e \u003ci\u003eFabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220\u003cbr\u003e \u003ci\u003eJoshua P. Loh and Ron Waksman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229\u003cbr\u003e \u003ci\u003eMichael A. Gaglia, Jr. and Ray V. Matthews\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237\u003cbr\u003e \u003ci\u003eAna Laynez and Ron Waksman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245\u003cbr\u003e \u003ci\u003eAung Myat, Yousif Ahmad, and Simon R. Redwood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253\u003cbr\u003e \u003ci\u003eSa'ar Minha and Ron Waksman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Bleeding Definitions, 259\u003cbr\u003e \u003ci\u003eSameer Bansilal, Deborah E. Aronson, and Roxana Mehran\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V: Antiplatelet Responsiveness\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e32 Personalizing Antiplatelet Therapy, 269\u003cbr\u003e \u003ci\u003ePaul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Aspirin Resistance, 277\u003cbr\u003e \u003ci\u003eMuthiah Vaduganathan and Eli I. Lev\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Clopidogrel Resistance, 285\u003cbr\u003e \u003ci\u003eUdaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Genetics of Clopidogrel Poor Response, 293\u003cbr\u003e \u003ci\u003ePierre Fontana and Jean-Luc Reny\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Proton Pump Inhibitors and Clopidogrel, 300\u003cbr\u003e \u003ci\u003eMichael A. Gaglia, Jr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Other Drug Interactions with Clopidogrel, 306\u003cbr\u003e \u003ci\u003eEric R. Bates\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 314\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Medicine: general issues [\u003ca title=\"See our other books on Medicine: general issues\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Medicine:%20general%20issues%20%5BMB%5D%22\"\u003eMB\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52417763311896,"sku":"9781118275757","price":55.87,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781118275757.jpg?v=1784507361","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/antiplatelet-therapy-in-cardiovascular-disease-hardback-9781118275757","provider":"Freshly Printed Books","version":"1.0","type":"link"}